Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Capital Group Private Client Services Inc.

Capital Group Private Client Services Inc. raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 95.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 119,218 shares of the biotechnology company's stock after purchasing an additional 58,335 shares during the quarter. Capital Group Private Client Services Inc. owned 0.12% of Sarepta Therapeutics worth $14,496,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after acquiring an additional 117,904 shares in the last quarter. Capital International Investors increased its position in Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after purchasing an additional 9,999 shares in the last quarter. Norges Bank purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $126,315,000. Finally, Erste Asset Management GmbH boosted its stake in shares of Sarepta Therapeutics by 11.3% during the fourth quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company's stock valued at $86,116,000 after purchasing an additional 72,183 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded up $1.60 during mid-day trading on Thursday, hitting $61.09. The company had a trading volume of 565,322 shares, compared to its average volume of 1,422,361. The company has a market capitalization of $5.93 billion, a price-to-earnings ratio of 48.98 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25. The company's fifty day moving average is $79.14 and its 200-day moving average is $106.58. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.70% of the company's stock.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company assumed coverage on Sarepta Therapeutics in a research note on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Morgan Stanley cut their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday, April 11th. Finally, Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $158.70.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.